Montpellier and Miami, December 11th 2024 – A specialist in the minimally invasive treatment of cancerous tumors, Quantum Surgical has just obtained ISO 27001:2023 certification, which attests to the security and rigor of its data management system.
The ISO/IEC 27001:2023 certification demonstrates that Quantum Surgical has implemented a robust and effective system to manage risks related to the security of its data or the data it processes. This system complies with the best practices and principles outlined in this international standard. Quantum Surgical’s clients can therefore be assured of the security of their data.
“Information and data security has always been a cornerstone of Quantum Surgical’s development. Our Epione solution is available in about ten hospitals worldwide; and obtaining the international ISO 27001:2023 certification reflects our commitment to our clients and users,” explains Bertin Nahum, CEO and co-founder of Quantum Surgical.
Quantum Surgical develops the Epione® robotic platform, which has been on the market since 2021. It assists practitioners in performing percutaneous tumor ablations, where one or more needles are inserted through the skin to destroy the tumor. This minimally invasive treatment provides patients with a safe and effective alternative to surgery.
Epione is now used in about ten centers worldwide, with over 700 patients already treated.
À propos de Quantum Surgical
Quantum Surgical is a French medical robotics company co-founded in 2017 by Bertin Nahum, CEO. With a dynamic team of over 110 employees, the company is headquartered in Montpellier, France, and has offices in Miami, Florida.
Its Epione® platform is dedicated to the curative and early treatment of cancers. Quantum Surgical thus offers a new approach to cancer treatment by standardizing access to care. More patients can benefit from innovative, better targeted and less invasive treatments. Hundreds of patients have already been treated worldwide.
Quantum Surgical a reçu le prestigieux Prix Galien USA en 2022, l'équivalent du Prix Nobel pour la recherche biopharmaceutique, et a rejoint en 2023 le programme gouvernemental French Tech 2030 qui soutient les meilleurs acteurs émergents en matière d'innovation de rupture.
Plus d'informations : www.quantumsurgical.com
Contact presse Quantum Surgical
Stéphanie Moy
s.moy@quantumsurgical.com
Tél. : +33 (0)6 32 55 85 48
